If a Woman has Hepatitis C Can She Have a Baby?

If a woman has Hepatitis C virus, also know as HCV, this will not prevent her for becoming pregnant. But there are issues to consider if a woman knows she has hepatitis and wants to have a child. A pregnancy will not adversely affect the health of a woman with HCV but it may put any more strain on the woman's liver. So it is very important to regularly check liver function, by the use of a simple blood test, throughout the pregnancy.

If the levels of infection in the bloodstream are very low then it is likely safe for her to get pregnant and not worry about transmission to the baby. But, if her levels are high, if she is already showing signs of liver damage, then there definitely is the possibility that she will transfer the infection to her child.  If a woman has high levels then there is a five to eight percent possibility of transmitting the Hepatitis C virus. Its much higher if the mother is also suffering from AIDS.

Doctors are not certain at what point the infection is given to the baby. They don't know if it's while in the womb or during the delivery. But they are reasonably certain it is not during conception. But breastfeeding is something that needs to be thought of carefully if a woman has the Hepatitis C virus. First, it should only be considered if the woman shows no signs of the infection. Second she should not breastfeed if she notices that her nipples have become cracked or are bleeding. This could pass the infection on to her baby especially if the baby has a cut anywhere in their mouth. 

It is difficult to determine directly after the birth if the baby is infected. In fact it can take several months before an answer is available. This is because the baby will have antibodies from the mother which make it appear that they are infected until they are between fifteen and eighteen months old when they disappear on their own. At this point testing can be done. Doctors and researchers are still trying to determine if a child is infected as a baby what the long-term results might be. Often even if infected the child will remain healthy in appearance and attitude for many years.

For certain treatments the doctors will set specific terms that must be agreed upon. For example, if a woman is about to begin a treatment period she must agree that both she and her partner will both use contraceptives during the entire treatment and for the six months afterwards in view of the fact that the medications are known to cause birth defects. The two drugs commonly used are interferon and ribavirin; it is the latter that can cause the defects.

Woman should know that having Hepatitis C does not stop them from being mothers and doing the things that are so much a part of motherhood like kissing and cuddling their children.

Hepatitis news on the Web

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover - BusinessWeek

RTT News

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover
BusinessWeek
3 (Bloomberg) -- Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in three years after one of the medicines produced positive clinical trial results.
Gilead Sciences jumps on hepatitis C dataCBS News
Gilead Woes With New Hep C Data, Boxing Out Poor 2012 GuidanceTheStreet.com
Gilead shares surge as hep C drug scores a cure for big patient populationFierceBiotech
Lagonian.com -Barron's (blog)
all 63 news articles »

Hepatitis Research May Benefit From Stem Cells - Medical News Today

MD News

Hepatitis Research May Benefit From Stem Cells
Medical News Today
Hepatitis C is a viral disease that leads to inflammation and organ failure. However, researchers are puzzled as to why some individuals are very susceptible to the disease, while others are not. Researchers believe they could find out how genetic ...
Personalized Liver Cells Support Hepatitis C VirusDoctors Lounge
Scientists establish HCV infection in liver-like cells derived from iPSCsNews-Medical.net

all 5 news articles »

Idenix gets good news on hep C trial, but can't compete with Gilead - FierceBiotech

Citybizlist

Idenix gets good news on hep C trial, but can't compete with Gilead
FierceBiotech
Idenix put out the news this morning that the FDA had lifted a partial hold on its hepatitis C drug IDX184--and then watched its share price slide. In a sign of just how volatile the whole hepatitis C arena has become after back-to-back blockbuster ...
Idenix Falls Casualty to Gilead Hep C HooplaTheStreet.com
Idenix: FDA lifts partial hold on hepatitis C drugMarketWatch
FDA removes hold on Idenix hep C drug targetMass High Tech
NASDAQ -Sacramento Bee
all 31 news articles »

HP awards Meg Whitman $16.5 million pay package - San Francisco Chronicle

HP awards Meg Whitman $16.5 million pay package
San Francisco Chronicle
Gilead's shares rose 11 percent on news a hepatitis C drug showed positive results in clinical trials. Gilead Sciences, the Foster City drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in ...

and more »

Vertex Hep C Sales Growth Nears End - TheStreet.com

Vertex Hep C Sales Growth Nears End
TheStreet.com
(TheStreet) -- Vertex Pharmaceuticals'(VRTX) fourth-quarter earnings report Thursday may represent the high-water sales mark for the hepatitis C drug Incivek -- with prescriptions already declining just seven months after launch.
Vertex Falls as Analyst Cuts Hep C Sales Estimate: Boston MoverBusinessWeek
Vertex shares drop as analyst cools on high-flying hep C drugBoston Business Journal
Vertex Falls as analyst cuts sales estimates on hepatitis C pillBoston Globe
LocalizedUSA
all 15 news articles »

Prosecutor says doctor in hepatitis C outbreak is faking disabilities. - Las Vegas Review - Journal

Washington Examiner

Prosecutor says doctor in hepatitis C outbreak is faking disabilities.
Las Vegas Review - Journal
Desai, 62, is challenging state medical experts who found him competent to stand trial on criminal charges in the 2007 hepatitis C outbreak. » Buy this photo By Jeff German Dr. Dipak Desai, the physician at the center of the hepatitis C outbreak, ...
Judge: Dipak Desai competent to stand trial in hepatitis caseLas Vegas Sun
Desai found competent to stand trialLas Vegas Review-Journal
Ex-doc ruled fit for trial in Vegas hep C caseWashington Examiner

all 15 news articles »

researchers identify peptide that inhibits replication of hepatitis C - UC Los Angeles

researchers identify peptide that inhibits replication of hepatitis C
UC Los Angeles
By Kim Irwin February 02, 2012 Category: Health Sciences, Research Researchers from UCLA's Jonsson Comprehensive Cancer Center have identified a cell-permeable peptide that inhibits a hepatitis C virus protein and blocks the viral replication that can ...

and more »

March trial for Desai may be postponed again - Las Vegas Review - Journal

March trial for Desai may be postponed again
Las Vegas Review - Journal
Buy this photo By Jeff German Dr. Dipak Desai may have been found competent to face criminal charges in the hepatitis C outbreak, but his upcoming March 12 trial is expected to be delayed again. Lawyers on both sides of the massive criminal case do not ...
FOX5 Vegas - KVVUDipak Desai found mentally fit to stand trialKVVU Las Vegas
Ex-doc ruled fit for trial in Vegas hepatitis-C caseMyNews3

all 5 news articles »

Vertex posts 4Q profit on growing Incivek sales - CBS News

Vertex posts 4Q profit on growing Incivek sales
CBS News
Drugmaker Vertex Pharmaceuticals Inc. said Thursday it turned a profit in the fourth quarter on sales of its hepatitis C pill Incivek, which was approved in May. Vertex reported a profit of $158.6 million, or 74 cents per share.
Curing Diseases Makes For a Bad Business ModelDailyFinance
Vertex roiled by fickle marketBizjournals.com
Vertex Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call TranscriptSeeking Alpha
Zacks.com
all 21 news articles »

Stem Cells May Further Hepatitis C Research - U.S. News & World Report

Stem Cells May Further Hepatitis C Research
U.S. News & World Report
31 (HealthDay News) -- Using stem cells to create liver-like cells for laboratory research may advance efforts to find out why people respond differently to hepatitis C infection, scientists say. It's not clear why some people are resistant to ...

and more »


Google News